Mode of action

AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

Retrieved on: 
Wednesday, March 6, 2024
Weed control, Corteva, Chemistry, Farmer, Mode of action, Moa, Crop protection, Herbicide, Agriculture, Mortality

The milestone marks the successful identification of a new family of molecules exhibiting herbicidal effect through a novel Mode of Action (MoA), APCO-12, discovered by AgPlenus.

Key Points: 
  • The milestone marks the successful identification of a new family of molecules exhibiting herbicidal effect through a novel Mode of Action (MoA), APCO-12, discovered by AgPlenus.
  • Most commercially available herbicides are based on small molecules that inhibit target proteins (MoAs) in weeds, leading to weed mortality.
  • Today, AgPlenus announced that, together with Corteva, they have identified a new potential class of herbicidal molecules through a novel MoA APCO-12.
  • Dr. Dan Gelvan, CEO of AgPlenus, said "we are excited about the milestone achieved in our collaboration with Corteva Agriscience, which reflects the synergy established between the teams.

GreenLight Biosciences Secures EPA Registration for New Bioinsecticide, Calantha, Historic Step Towards A Safer and More Sustainable Food System

Retrieved on: 
Thursday, January 4, 2024
RNA, Classification, Insecticide Resistance Action Committee, Butterfly, Farmer, Health, Herbicide, Mode of action, Green-light, MITES, Crop protection, Environmental health, Mammal, Plant, Water, EPA, Pesticide, Soil, Environment, Agriculture

Following the federal and state approvals, the company has now successfully sold and shipped its first order.

Key Points: 
  • Following the federal and state approvals, the company has now successfully sold and shipped its first order.
  • "The registration of Calantha marks not just a milestone for our company, but a quantum leap for farmers, our food system and security, and people," said Andrey Zarur, Chief Executive Officer, GreenLight Bio.
  • We are thrilled to witness the impending impact of this commercial chapter of our company in creating a more sustainable future."
  • GreenLight Bio's breakthrough platform, capable of economically producing dsRNA, fuels its robust pipeline of additional innovative insecticides, fungicides and herbicides.

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

Retrieved on: 
Tuesday, May 30, 2023
SON, Survivor, Alkalihalobacillus clausii, IR, Biotechnology, Prevalence, Pancreatic cancer, Bacteriophage, Drug discovery, Survival, Open reading frame, Mode of action, Cancer, STS, Radio spectrum, Research, DSM-IV codes, Colorectal cancer, Acquisition, Parkinson's disease, Patient, Pancreas, Immune system, Intron, Mode, Growth, Bacteria, Mall of America, Recurrence, LTS, Alzheimer's disease, Genome, Vaccine, Pharmaceutical industry, Large intestine, Prophage

BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.

Key Points: 
  • BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.
  • The ultimate goal is to develop phage-based immunotherapeutics capable of treating a range of immune disorders including cancer.
  • The primary focus of the company lies in Colorectal cancer and Pancreatic cancer.
  • Alkalihalobacillus clausii has been identified as a representative microbiome, and iNtRON has obtained the strain and confirmed the presence of Prophage and Jamphage through the genomic analysis.

Vesselon Discovery Protects and Expands Drug Franchises

Retrieved on: 
Monday, May 22, 2023
Liposome, Tissue, Pancreatic cancer, Mode of action, Spencer Trask & Co., Myriad Genetics, Cell, IP, Therapeutic index, Malignancy, Genetics, Protein, Dicarboxylic acid, Publication, Patent, Risk, Peptide, Potyvirus, Neoplasm, Cytokine, Osiris Therapeutics, FDA, Therapy, Safety, Pharmaceutical industry, Vaccine, Medical imaging

GREENWICH, Conn., May 22, 2023 /PRNewswire/ -- In a major development, Vesselon has discovered how to protect a superior method of delivering drugs shown to be effective in more than 1,700 independent preclinical and clinician-sponsored human trials. Despite compelling evidence that the method improves the Therapeutic Index of numerous drugs in many indications, its promise has been ignored by the pharmaceutical industry because it has not been patentable, until now.

Key Points: 
  • Based on this discovery, the drug maker has filed patents on its TriForm™ lipid platform.
  • The on-site, in-vial mixing process instantly combines a therapeutic drug with the FDA-approved Vesselon lipid microsphere shown to have the same safety level as saline.
  • After mixing a standard dose, each vial contains approximately 10 billion lipid microspheres encapsulating the active drug, 50 trillion liposomes loaded with the active drug, as well as the freely circulating drug.
  • In addition to existing franchises, current and future pipeline drugs will also benefit from the Vesselon platform.

Lavie Bio Reports Successful Results for its Bio-Fungicides Programs

Retrieved on: 
Tuesday, February 28, 2023
Death, Disease resistance, Agriculture, Lavie, Artificial intelligence, Fungus, China Biologic Products, IPM, MOA, Fungal infection, Algorithm, Nutrient, Botrytis cinerea, Integrated pest management, Environment, Plant, Mode of action, Vegetable, BDD, Food quality, TASE, Wilting, United States Environmental Protection Agency, Fruit, Oomycete, EPA, Viticulture, Pharmaceutical industry

REHOVOT, Israel, Feb. 28, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced progress in its bio-fungicides programs based on successful results from field trials conducted in 2022 for its bio-fungicides LAV311 and LAV321, after conclusion of the analysis of its statistic results.

Key Points: 
  • Lavie Bio's product candidates LAV311 and LAV321 are bio-fungicides that were discovered and developed utilizing Lavie Bio's Biology Driven Design (BDD) platform, based on Evogene's MicroBoost AI tech-engine which leverages big-data and advanced artificial intelligence (AI) algorithms.
  • Lavie Bio's bio-fungicide product LAV311 is an optimized live microbial strain that has an indirect Mode of Action (MOA) competing with harmful fungi over space and nutrients.
  • Commented Dor Kestecher, VP Business Development at Lavie Bio, "We are very pleased with the progress of our internal bio-fungicide programs, focused on providing biological solutions for key diseases in fruits and vegetables.
  • LAV311's positive results on vine bunch rots and powdery mildew, may represent a significant potential market in the US and Europe.

Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus

Retrieved on: 
Monday, August 1, 2022
Vaccine, Severe acute respiratory syndrome coronavirus 2, Pulmonary fibrosis, GLOBE, Galectin, Degenerative disease, Protein, Human, Outline, Journal, COVID-19, Carbohydrate, Fibrosis, Autophagy, MOA, Nature, Cancer, Virology, Outline of health sciences, Cell, Glycoconjugate, Clinical trial, Inflammation, Viral load, Patient, Coronavirus, Mode of action, Stroke, Lists of World Heritage Sites, Control, Article, Variants of SARS-CoV-2, Canadian International Council, Hypoxia, Pharmaceutical industry, Lectin

BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below. ProLectin-M is the Company’s leading drug molecule in its pipeline to treat viral infections.

Key Points: 
  • ProLectin-M is the Companys leading drug molecule in its pipeline to treat viral infections.
  • The journal article begins to outline and further define the mechanism of action (MOA) behind the oral galectin inhibitor Prolectin-M.
  • The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases and bind to the conserved region of the spike protein commonly known as the galectin fold.
  • ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus.

Evogene Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 11, 2021
Olam, Administration, Inflammation, Business development, Agriculture, Breast cancer, Health, LAV, IBD, Castor oil, Company, G&A, Computational biology, Operating cost, Exercise, Biology, CPB, GMP, BD, ATM, Technology, Conference, Program, Coal gasification commercialization, Gene, Melanoma, Computation, Clinical trial, Artificial intelligence, Corteva, COVID-19, Herbicide, Risk, Insurance, Farmer, Burn, Mode of action, TASE, ICI, NASDAQ, Webcast, Marketing, Research, Lead, Research and development, Fine chemical, Medical imaging, Pharmaceutical industry, Renewable energy, Antibiotics, Video game console, Bank, Ridesharing company, Internet service provider

REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the first half and the second quarter of 2021, ended June 30, 2021.

Key Points: 
  • REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the first half and the second quarter of 2021, ended June 30, 2021.
  • Business Development ("BD") expenses: Business Development expenseswere $0.7 million for the second quarter of 2021, in comparison to $0.5 million in the second quarter of 2020.
  • Operating loss: Operating loss for the second quarter of 2021 was $7.4 million in comparison to $5.2 million in the second quarter of 2020.
  • Net loss:The net loss for the second quarter of 2021 was $6.9 million in comparison to a net loss of $4.8 million during second quarter of 2020.